Special Issue "Targeted Human Cytolytic Fusion Proteins"
Deadline for manuscript submissions: closed (31 October 2017) | Viewed by 20671
2. South African Research Chair in Cancer Biotechnology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town 7700, South Africa
Interests: knowledge-driven development of disease-specific diagnostic and therapeutic solutions for unmet medical need
This Special Issue, “Targeted Human Cytolytic Fusion Proteins”, will focus on current advances in research using targeted approaches for disease-selective induction of apoptosis. Recombinant immunotoxins have traditionally combined an antibody targeting a specific cell of interest with a potent cell killing protein/enzyme derived from bacteria or plants. However, reduction in immunogenicity by use of T- and B-cell epitope-depleted bacterial toxins as well as their replacement by human enzymes has resulted in safer and more efficacious fusion proteins.
We cordially invite authors in the field to submit original research or review articles pertaining to this highly expanding field of recombinant immunotherapeutics. Specifically, colleagues working in the following areas are particularly encouraged to submit manuscripts: recombinant antibody technologies to select and identify promising internalizing cell surface receptors for disease-specific targeting, the use of protein engineering to combine these specific ligands with highly effective apoptosis-inducing enzymes, strategies to improve efficient delivery of the catalytic subunits into the intracellular compartments of choice, in silico methods to rationally improve function of hCFP, and lastly endeavours to break any reported resistance of hCFP function.
We look forward to receiving novel and high impact content from contributors.
Prof. Dr. Stefan Barth
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- fusion proteins
- antibody technologies
- cytolytic enzymes